• Zacks Investment Research Upgrades Capricor Therapeutics (NASDAQ:CAPR) to “Buy”

    Zacks Investment Research upgraded shares of Capricor Therapeutics (NASDAQ:CAPR) from a hold rating to a buy rating in a research report …

    Read More
  • 0 0